See every side of every news story
Published loading...Updated

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC - Innoviva (NASDAQ:INVA), Armata Pharmaceuticals (AMEX:ARMP)

Summary by Ground News
The gross proceeds to the Company from the transaction are $30 million, before deducting estimated transaction-related expenses payable by the Company. Armata intends to use the net proceeds from this transaction to continue clinical development of AP-PA02 and AP-SA02. These funds will finance the completion of an advanced biologics cGMP manufacturing facility with the technology to support production of complex multi- component phage therapeutics.

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States on Tuesday, January 10, 2023.
Sources are mostly out of (0)

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.